Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leht 1 alates 17 tulemused
Peptide sequence that promotes tumor invasion
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
The genetic basis of cancer dissemination, also known as metastasis, has been subject to intense debate. Metastasis genes have been identified as stress response genes, which in cancer are deregulated on the levels of aberrant expression and splicing.
Osteopontin is a cytokine that is
Peptide sequence that promotes tumor invasion
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
The genetic basis of cancer dissemination, also known as metastasis, has been subject to intense debate. Metastasis genes have been identified as stress response genes, which in cancer are deregulated on the levels of aberrant expression and splicing.
Osteopontin is a cytokine that is
Methods for the suppression of neu mediated tumors by the adenoviral EIA gene
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to methodology and associated genetic constructs for the suppression of oncogene-mediated, transformation, tumorigenesis and metastasis. In particular, this invention relates to the suppression of oncogenesis that is mediated by the HER-2/c-erb B-2/neu oncogene, an
Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
A. Field of the Invention
The present invention relates to methodology and associated genetic constructs for the suppression of oncogene-mediated, transformation, tumorigenesis and metastasis. In particular, this invention relates to the suppression of oncogenesis that is mediated by the HER-2/c-erb
Methods for the suppression of neu mediated phenotype in tumors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
A. Field of the Invention
The present invention relates to methodology and associated genetic constructs for the suppression of oncogene-mediated, transformation, tumorigenesis and metastasis. In particular, this invention relates to the suppression of oncogenesis that is
Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
A. Field of the Invention
The present invention relates to methodology and associated genetic constructs for the suppression of oncogene-mediated, transformation, tumorigenesis and metastasis. In particular, this invention relates to the suppression of oncogenesis that is
Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the field of cancer and also to polypeptides with growth-promoting activities. The invention is particularly directed to the identification of growth factors, primarily from bone and prostate tissues,
Targeting metabolic enzymes in human cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS-REFERENCE TO RELATED APPLICATION
This application is a national stage filing under 35 U.S.C. .sctn.371 of international application PCT/SG2011/000400, filed Nov. 11, 2011, which claims priority to Singapore Application No. 201008288-1, filed Nov. 11, 2010, the contents of all of which are
Nucleophosmin/B23-binding peptide to inhibit tumor growth and regulate transcriptional activity of p53
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to tumors. More specifically, the present invention discloses a method of inhibiting tumor growth and up-regulating transcriptional activity of p53 by utilizing Nucleophosmin/B23-binding peptide.
2. Description of
Contrast resolution tissue mimicking phantoms for nuclear magnetic resonance imaging with stable NMR properties
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention pertains generally to products and techniques for testing the resolution capabilities of nuclear magnetic resonance (NMR) imaging equipment and particularly to imaging processes in which hydrogen is the monitored nucleus.
BACKGROUND OF THE INVENTION
The early
Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention relates to genes which encode novel proteins related to a family of receptor proteins typified by two related membrane spanning tyrosinc kinases: the Epidermal Growth Factor receptor (EGFR), which is encoded by the erbB gene, the normal human counterpart
Recombinant DNA encoding an epidermal growth factor receptor related protein
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention relates to the epidermal growth factor related proteins, polynucleotides encoding these proteins and methods for using these proteins. The cellular machinery involved in mitogenesis is complex, and not yet fully understood. In general, receptors present on the
Isolation and characterization of a rat epidermal growth factor related protein
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention relates to the epidermal growth factor related proteins, polynucleotides encoding these proteins and methods for using these proteins. The cellular machinery involved in mitogenesis is complex, and not yet fully understood. In general, receptors present on the
Capsules for oral preparations and capsule preparations for oral administration
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
1. Background of the Invention
This invention relates to capsules for preparations for oral administration and also to capsule preparations for oral administration using said capsules. More particularly, this invention relates to capsules being able to be administered orally
p40 protein acts as an oncogene
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD OF THE INVENTION
This invention is related to the field of cancer diagnostics and therapeutics.
BACKGROUND OF THE INVENTION
p53 is the most commonly inactivated gene in human cancer and loss of critical p53 pathways are central to tumorigenesis.sup.1,2. The p53 protein binds specific
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
